

Günter U Höglinger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1238772/publications.pdf>

Version: 2024-02-01

251
papers

20,000
citations

17440

63
h-index

12597

132
g-index

267
all docs

267
docs citations

267
times ranked

28403
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Seizure prevalence in neurodegenerative diseasesâ€”a study of autopsy proven cases. <i>European Journal of Neurology</i> , 2022, 29, 12-18. | 3.3 | 6 |
| 2 | One-year outcome of brain injured patients undergoing early neurological rehabilitation: a prospective observational study. <i>BMC Neurology</i> , 2022, 22, 30. | 1.8 | 8 |
| 3 | Innovative therapeutic concepts of progressive multifocal leukoencephalopathy. <i>Journal of Neurology</i> , 2022, 269, 2403-2413. | 3.6 | 12 |
| 4 | Neuropsychiatric Symptoms in Parkinsonâ€™s Disease Patients Are Associated with Reduced Health-Related Quality of Life and Increased Caregiver Burden. <i>Brain Sciences</i> , 2022, 12, 89. | 2.3 | 17 |
| 5 | Neurological management and work-up of neurotoxicity associated with CAR T cell therapy. <i>Neurological Research and Practice</i> , 2022, 4, 1. | 2.0 | 9 |
| 6 | Impact of Partial Volume Correction on [18F]GE-180 PET Quantification in Subcortical Brain Regions of Patients with Corticobasal Syndrome. <i>Brain Sciences</i> , 2022, 12, 204. | 2.3 | 2 |
| 7 | Longitudinal changes of early motor and cognitive symptoms in progressive supranuclear palsy: the OxQUIP study. <i>BMJ Neurology Open</i> , 2022, 4, e000214. | 1.6 | 5 |
| 8 | Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinsonâ€™s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial. <i>Journal of Parkinson's Disease</i> , 2022, 12, 557-570. | 2.8 | 34 |
| 9 | Tau deposition patterns are associated with functional connectivity in primary tauopathies. <i>Nature Communications</i> , 2022, 13, 1362. | 12.8 | 34 |
| 10 | Reduction in Volume of Nucleus Basalis of Meynert Is Specific to Parkinsonâ€™s Disease and Progressive Supranuclear Palsy but Not to Multiple System Atrophy. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 851788. | 3.4 | 7 |
| 11 | The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 1131-1148. | 3.9 | 222 |
| 12 | Transcriptome and Proteome Analysis in LUHMES Cells Overexpressing Alpha-Synuclein. <i>Frontiers in Neurology</i> , 2022, 13, 787059. | 2.4 | 9 |
| 13 | Binding Stability of Antibodyâ€”Synuclein Complexes Predicts the Protective Efficacy of Anti-Î±-synuclein Antibodies. <i>Molecular Neurobiology</i> , 2022, 59, 3980-3995. | 4.0 | 3 |
| 14 | A new paradigm for diagnosis of neurodegenerative diseases: peripheral exosomes of brain origin. <i>Translational Neurodegeneration</i> , 2022, 11, 28. | 8.0 | 37 |
| 15 | Inferring the sequence of brain volume changes in progressive supranuclear palsy using MRI. <i>Brain Communications</i> , 2022, 4, . | 3.3 | 1 |
| 16 | Comparative analysis of machine learning algorithms for multi-syndrome classification of neurodegenerative syndromes. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 62. | 6.2 | 9 |
| 17 | GBA-associated PD: chances and obstacles for targeted treatment strategies. <i>Journal of Neural Transmission</i> , 2022, 129, 1219-1233. | 2.8 | 22 |
| 18 | In Vivo Assessment of Neuroinflammation in <sc>4â€Repeat</sc> Tauopathies. <i>Movement Disorders</i> , 2021, 36, 883-894. | 3.9 | 37 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. <i>Lancet Neurology, The</i> , 2021, 20, 107-116. | 10.2 | 62 |
| 20 | The influence of the CRS-R score on functional outcome in patients with severe brain injury receiving early rehabilitation. <i>BMC Neurology</i> , 2021, 21, 44. | 1.8 | 13 |
| 21 | The "œzig-zag" sign in progressive supranuclear palsy " The slowness of vertical saccades was the clue. <i>Parkinsonism and Related Disorders</i> , 2021, 83, 6-7. | 2.2 | 0 |
| 22 | Auditory Stimulation Modulates Resting-State Functional Connectivity in Unresponsive Wakefulness Syndrome Patients. <i>Frontiers in Neuroscience</i> , 2021, 15, 554194. | 2.8 | 7 |
| 23 | One Year Trajectory of Caregiver Burden in Parkinson's Disease and Analysis of Gender-Specific Aspects. <i>Brain Sciences</i> , 2021, 11, 295. | 2.3 | 19 |
| 24 | Outcomes of SARS-CoV-2 Infections in Patients with Neurodegenerative Diseases in the LEOSS Cohort. <i>Movement Disorders</i> , 2021, 36, 791-793. | 3.9 | 13 |
| 25 | Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. <i>Lancet Neurology, The</i> , 2021, 20, 182-192. | 10.2 | 74 |
| 26 | First symptom guides diagnosis and prognosis in neurodegenerative diseases" a retrospective study of autopsy proven cases. <i>European Journal of Neurology</i> , 2021, 28, 1801-1811. | 3.3 | 11 |
| 27 | Genotype-Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review. <i>Movement Disorders</i> , 2021, 36, 1499-1510. | 3.9 | 22 |
| 28 | Evidence for pathogenicity of variant ATM Val1729Leu in a family with ataxia telangiectasia. <i>Neurogenetics</i> , 2021, 22, 143-147. | 1.4 | 2 |
| 29 | Comprehensive miRNome-Wide Profiling in a Neuronal Cell Model of Synucleinopathy Implies Involvement of Cell Cycle Genes. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 561086. | 3.7 | 9 |
| 30 | Clinical Features Observed in General Practice Associated With the Subsequent Diagnosis of Progressive Supranuclear Palsy. <i>Frontiers in Neurology</i> , 2021, 12, 637176. | 2.4 | 9 |
| 31 | Prothrombotic immune thrombocytopenia after COVID-19 vaccination. <i>Blood</i> , 2021, 138, 350-353. | 1.4 | 145 |
| 32 | DescribePSP and ProPSP: German Multicenter Networks for Standardized Prospective Collection of Clinical Data, Imaging Data, and Biomaterials of Patients With Progressive Supranuclear Palsy. <i>Frontiers in Neurology</i> , 2021, 12, 644064. | 2.4 | 3 |
| 33 | Validation of the Parkinson's Disease Caregiver Burden Questionnaire in Progressive Supranuclear Palsy. <i>Parkinson's Disease</i> , 2021, 2021, 1-7. | 1.1 | 3 |
| 34 | Cortical [¹⁸ F]PI-2620 Binding Differentiates Corticobasal Syndrome Subtypes. <i>Movement Disorders</i> , 2021, 36, 2104-2115. | 3.9 | 46 |
| 35 | Allogeneic BK Virus-Specific T-Cell Treatment in 2 Patients With Progressive Multifocal Leukoencephalopathy. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, e1020. | 6.0 | 19 |
| 36 | Binding characteristics of [¹⁸ F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 2957-2972. | 4.3 | 30 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3872-3885. | 6.4 | 22 |
| 38 | Dual-Phase β -Amyloid PET Captures Neuronal Injury and Amyloidosis in Corticobasal Syndrome. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 661284. | 3.4 | 13 |
| 39 | Impact of TSPO Receptor Polymorphism on [18F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders. <i>Life</i> , 2021, 11, 484. | 2.4 | 11 |
| 40 | Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database. <i>Frontiers in Neurology</i> , 2021, 12, 571800. | 2.4 | 14 |
| 41 | Relationship Satisfaction in People with Parkinson's Disease and Their Caregivers: A Cross-Sectional Observational Study. <i>Brain Sciences</i> , 2021, 11, 822. | 2.3 | 11 |
| 42 | Non-invasive and high-throughput interrogation of exon-specific isoform expression. <i>Nature Cell Biology</i> , 2021, 23, 652-663. | 10.3 | 11 |
| 43 | Differential expression of gut miRNAs in idiopathic Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 88, 46-50. | 2.2 | 8 |
| 44 | Atypical pantothenate kinase-associated neurodegeneration with variable phenotypes in an Egyptian family. <i>Heliyon</i> , 2021, 7, e07469. | 3.2 | 0 |
| 45 | Superiority of Formalin-Fixed Paraffin-Embedded Brain Tissue for in vitro Assessment of Progressive Supranuclear Palsy Tau Pathology With [18F]PI-2620. <i>Frontiers in Neurology</i> , 2021, 12, 684523. | 2.4 | 11 |
| 46 | Does the Anti-Tau Strategy in Progressive Supranuclear Palsy Need to Be Reconsidered? <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1038-1040. | 1.5 | 5 |
| 47 | COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany. <i>Annals of Neurology</i> , 2021, 90, 627-639. | 5.3 | 122 |
| 48 | Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies. <i>Nature Reviews Neurology</i> , 2021, 17, 601-620. | 10.1 | 41 |
| 49 | Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease. <i>Neurology</i> , 2021, 97, . | 1.1 | 50 |
| 50 | iPS Cell-Based Model for MAPT Haplotype as a Risk Factor for Human Tauopathies Identifies No Major Differences in TAU Expression. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 726866. | 3.7 | 4 |
| 51 | Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. <i>Nature Medicine</i> , 2021, 27, 1451-1457. | 30.7 | 63 |
| 52 | Alpha-Synuclein defects autophagy by impairing SNAP29-mediated autophagosome-lysosome fusion. <i>Cell Death and Disease</i> , 2021, 12, 854. | 6.3 | 39 |
| 53 | Neurological symptoms and complications in predominantly hospitalized COVID-19 patients: Results of the European multinational Lean European Open Survey on SARS-CoV-2 Infected Patients (LEOSS). <i>European Journal of Neurology</i> , 2021, 28, 3925-3937. | 3.3 | 25 |
| 54 | Treatment of upper limb spasticity with inhibitory repetitive transcranial magnetic stimulation: A randomized placebo-controlled trial. <i>NeuroRehabilitation</i> , 2021, 49, 425-434. | 1.3 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Neuropathology of progressive supranuclear palsy after treatment with tilavonemab â€“ Author's reply. <i>Lancet Neurology</i> , The, 2021, 20, 787-788. | 10.2 | 3 |
| 56 | PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642199368. | 3.5 | 9 |
| 57 | A Modified Progressive Supranuclear Palsy Rating Scale. <i>Movement Disorders</i> , 2021, 36, 1203-1215. | 3.9 | 13 |
| 58 | Reply to: â€œApplication of the <scp>mPSPRS</scp> to the Salerno Cohortâ€•. <i>Movement Disorders</i> , 2021, 36, 2451-2452. | 3.9 | 0 |
| 59 | Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases. <i>Science Translational Medicine</i> , 2021, 13, eabe5640. | 12.4 | 108 |
| 60 | Cerebral Microstructural Alterations in Patients With Early Parkinsonâ€™s Disease Detected With Quantitative Magnetic Resonance Measurements. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 763331. | 3.4 | 5 |
| 61 | Analysis of Transition of Patients with Parkinsonâ€™s Disease into Institutional Care: A Retrospective Pilot Study. <i>Brain Sciences</i> , 2021, 11, 1470. | 2.3 | 9 |
| 62 | Patient Safety in a Box: Implementation and Evaluation of the Emergency Box in Geriatric and Parkinson Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 5618. | 2.4 | 1 |
| 63 | Associations between sex, body mass index, and the individual microglial response in Alzheimerâ€™s disease. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 64 | Can SARS-CoV-2 Infection Lead to Neurodegeneration and Parkinsonâ€™s Disease?. <i>Brain Sciences</i> , 2021, 11, 1654. | 2.3 | 22 |
| 65 | Feasibility of short imaging protocols for [¹⁸ F]Piâ€2620 tauâ€PET in progressive supranuclear palsy. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 66 | Validation of the Movement Disorder Society Criteria for the Diagnosis of 4â€Repeat Tauopathies. <i>Movement Disorders</i> , 2020, 35, 171-176. | 3.9 | 37 |
| 67 | Disease-modifying strategies in primary tauopathies. <i>Neuropharmacology</i> , 2020, 167, 107842. | 4.1 | 7 |
| 68 | Loss of fragile X mental retardation protein precedes Lewy pathology in Parkinsonâ€™s disease. <i>Acta Neuropathologica</i> , 2020, 139, 319-345. | 7.7 | 17 |
| 69 | Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 200-203. | 2.2 | 8 |
| 70 | How specific are non-motor symptoms in the prodrome of Parkinson's disease compared to other movement disorders?. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 213-218. | 2.2 | 8 |
| 71 | Alexithymia Is Associated with Reduced Quality of Life and Increased Caregiver Burden in Parkinsonâ€™s Disease. <i>Brain Sciences</i> , 2020, 10, 401. | 2.3 | 18 |
| 72 | Longitudinal TSPO expression in tau transgenic P301S mice predicts increased tau accumulation and deteriorated spatial learning. <i>Journal of Neuroinflammation</i> , 2020, 17, 208. | 7.2 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Reply to: "Brief Clinical Rating Scales Should Not Be Overlooked": Movement Disorders, 2020, 35, 1886-1886. | 3.9 | 3 |
| 74 | Basic Fibroblast Growth Factor 2-Induced Proteome Changes Endorse Lewy Body Pathology in Hippocampal Neurons. Science, 2020, 23, 101349. | 4.1 | 4 |
| 75 | Postinfectious Onset of Myasthenia Gravis in a COVID-19 Patient. Frontiers in Neurology, 2020, 11, 576153. | 2.4 | 64 |
| 76 | FGF2 Affects Parkinson's Disease-Associated Molecular Networks Through Exosomal Rab8b/Rab31. Frontiers in Genetics, 2020, 11, 572058. | 2.3 | 12 |
| 77 | Brain Morphological Alterations Are Detected in Early-Stage Parkinson's Disease with MRI Morphometry. Journal of Neuroimaging, 2020, 30, 786-792. | 2.0 | 8 |
| 78 | Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. Movement Disorders Clinical Practice, 2020, 7, 750-762. | 1.5 | 31 |
| 79 | Clinical Conditions "Suggestive of Progressive Supranuclear Palsy" Diagnostic Performance. Movement Disorders, 2020, 35, 2301-2313. | 3.9 | 22 |
| 80 | Assessment of ¹⁸ F-Pi-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurology, 2020, 77, 1408. | 9.0 | 145 |
| 81 | Hospitalization Rates and Comorbidities in Patients with Progressive Supranuclear Palsy in Germany from 2010 to 2017. Journal of Clinical Medicine, 2020, 9, 2454. | 2.4 | 3 |
| 82 | Glial activation is moderated by sex in response to amyloidosis but not to tau pathology in mouse models of neurodegenerative diseases. Journal of Neuroinflammation, 2020, 17, 374. | 7.2 | 28 |
| 83 | Microglial activation in vivo is moderated by sex in response to amyloidosis but not to tau pathology in mouse models of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e039574. | 0.8 | 0 |
| 84 | ¹⁸ F-Pi-2620 tau-PET in corticobasal syndrome (ActiGliA cohort). Alzheimer's and Dementia, 2020, 16, e041469. | 0.8 | 1 |
| 85 | Microglial activation and brain networks in Alzheimer's disease: The ActiGliA cohort study. Alzheimer's and Dementia, 2020, 16, e043265. | 0.8 | 0 |
| 86 | Reply to: "Letter to the Editor on "Copathology Progressive Supranuclear Palsy: Does It Matter?"". Movement Disorders, 2020, 35, 2126-2126. | 3.9 | 2 |
| 87 | Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathologica, 2020, 140, 99-119. | 7.7 | 210 |
| 88 | Copathology in Progressive Supranuclear Palsy: Does It Matter?. Movement Disorders, 2020, 35, 984-993. | 3.9 | 48 |
| 89 | Author response: Use of β -adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease. Neurology, 2020, 94, 899-899. | 1.1 | 0 |
| 90 | Longitudinal correlation between neurofilament light chain and UMSARS in Multiple System Atrophy. Clinical Neurology and Neurosurgery, 2020, 195, 105924. | 1.4 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 91 | Fibroblast Growth Factor 2â€Mediated Regulation of Neuronal Exosome Release Depends on VAMP3/Cellubrevin in Hippocampal Neurons. <i>Advanced Science</i> , 2020, 7, 1902372. | 11.2 | 33 |
| 92 | Mindfulness and Psychological Flexibility are Inversely Associated with Caregiver Burden in Parkinsonâ€™s Disease. <i>Brain Sciences</i> , 2020, 10, 111. | 2.3 | 16 |
| 93 | Consensus-Based Recommendations for Advance Directives of People with Parkinsonâ€™s Disease in Regard to Typical Complications by German Movement Disorder Specialists. <i>Journal of Clinical Medicine</i> , 2020, 9, 449. | 2.4 | 7 |
| 94 | The Progressive Supranuclear Palsy Clinical Deficits Scale. <i>Movement Disorders</i> , 2020, 35, 650-661. | 3.9 | 31 |
| 95 | Î²-adrenoreceptors and the risk of Parkinson's disease. <i>Lancet Neurology</i> , The, 2020, 19, 247-254. | 10.2 | 49 |
| 96 | Alpha-synuclein fragments trigger distinct aggregation pathways. <i>Cell Death and Disease</i> , 2020, 11, 84. | 6.3 | 19 |
| 97 | Rare Variants in Specific Lysosomal Genes Are Associated With Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1245-1248. | 3.9 | 37 |
| 98 | Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2911-2922. | 6.4 | 36 |
| 99 | Looking into the prediagnostic phase of progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2020, 74, 74-75. | 2.2 | 1 |
| 100 | Private variants in PRKN are associated with late-onset Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 75, 24-26. | 2.2 | 4 |
| 101 | A call for a global COVID-19 Neuro Research Coalition. <i>Lancet Neurology</i> , The, 2020, 19, 482-484. | 10.2 | 22 |
| 102 | <sc><i>LRP1</i></sc>: A Novel Mediator of Tau Uptake. <i>Movement Disorders</i> , 2020, 35, 1136-1136. | 3.9 | 1 |
| 103 | Towards a consensus on developmental regression. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 107, 3-5. | 6.1 | 14 |
| 104 | One decade ago, one decade ahead in progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 1284-1293. | 3.9 | 12 |
| 105 | Tau links developmental to neurodegenerative diseases. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 104, 26-27. | 6.1 | 1 |
| 106 | Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2019, 18, 724-735. | 10.2 | 79 |
| 107 | Neuronal precursor cells with dopaminergic commitment in the rostral migratory stream of the mouse. <i>Scientific Reports</i> , 2019, 9, 13359. | 3.3 | 12 |
| 108 | PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 249. | 3.4 | 30 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Use of β -adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease. <i>Neurology</i> , 2019, 93, e135-e142. | 1.1 | 29 |
| 110 | Four-repeat tauopathies. <i>Progress in Neurobiology</i> , 2019, 180, 101644. | 5.7 | 141 |
| 111 | A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 975-984. | 3.9 | 73 |
| 112 | Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease. <i>Brain</i> , 2019, 142, 1429-1440. | 7.6 | 36 |
| 113 | How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 1228-1232. | 3.9 | 93 |
| 114 | Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients. <i>Drugs and Aging</i> , 2019, 36, 511-530. | 2.7 | 38 |
| 115 | Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 301-309. | 2.4 | 30 |
| 116 | Multiple molecular pathways stimulating macroautophagy protect from alpha-synuclein-induced toxicity in human neurons. <i>Neuropharmacology</i> , 2019, 149, 13-26. | 4.1 | 14 |
| 117 | Unbiased Screens for Modifiers of Alpha-Synuclein Toxicity. <i>Current Neurology and Neuroscience Reports</i> , 2019, 19, 8. | 4.2 | 8 |
| 118 | Mitochondrial damage by α -synuclein causes cell death in human dopaminergic neurons. <i>Cell Death and Disease</i> , 2019, 10, 865. | 6.3 | 112 |
| 119 | Classification of atypical parkinsonism per pathology versus phenotype. <i>International Review of Neurobiology</i> , 2019, 149, 37-47. | 2.0 | 10 |
| 120 | Genetic mimics of the non-genetic atypical parkinsonian disorders – the "atypical" atypical. <i>International Review of Neurobiology</i> , 2019, 149, 327-351. | 2.0 | 8 |
| 121 | Progressive supranuclear palsy. <i>International Review of Neurobiology</i> , 2019, 149, 49-86. | 2.0 | 19 |
| 122 | Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 138-145. | 2.2 | 7 |
| 123 | Pearls & Oysters: Ocular motor apraxia as essential differential diagnosis to supranuclear gaze palsy. <i>Neurology</i> , 2018, 90, 482-485. | 1.1 | 10 |
| 124 | CXCR4 involvement in neurodegenerative diseases. <i>Translational Psychiatry</i> , 2018, 8, 73. | 4.8 | 66 |
| 125 | Selective Genetic Overlap Between Amyotrophic Lateral Sclerosis and Diseases of the Frontotemporal Dementia Spectrum. <i>JAMA Neurology</i> , 2018, 75, 860. | 9.0 | 79 |
| 126 | Is it Useful to Classify Progressive Supranuclear Palsy and Corticobasal Degeneration as Different Disorders? No. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 141-144. | 1.5 | 28 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 127 | Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. <i>Neurology</i> , 2018, 90, 74-82. | 1.1 | 23 |
| 128 | Symptomatic therapy of multiple system atrophy. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2018, 211, 26-30. | 2.8 | 18 |
| 129 | K-variant BCHE and pesticide exposure: Gene-environment interactions in a case-control study of Parkinson's disease in Egypt. <i>Scientific Reports</i> , 2018, 8, 16525. | 3.3 | 21 |
| 130 | Epigenome-wide DNA methylation profiling in Progressive Supranuclear Palsy reveals major changes at DLX1. <i>Nature Communications</i> , 2018, 9, 2929. | 12.8 | 20 |
| 131 | Variation at the <i>TRIM11</i> locus modifies progressive supranuclear palsy phenotype. <i>Annals of Neurology</i> , 2018, 84, 485-496. | 5.3 | 37 |
| 132 | Exosomal secretion of α -synuclein as protective mechanism after upstream blockage of macroautophagy. <i>Cell Death and Disease</i> , 2018, 9, 757. | 6.3 | 117 |
| 133 | Progressive supranuclear palsy and multiple system atrophy: clinicopathological concepts and therapeutic challenges. <i>Current Opinion in Neurology</i> , 2018, 31, 448-454. | 3.6 | 19 |
| 134 | New classification of tauopathies. <i>Revue Neurologique</i> , 2018, 174, 664-668. | 1.5 | 39 |
| 135 | Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. <i>PLoS Medicine</i> , 2018, 15, e1002487. | 8.4 | 111 |
| 136 | Manual MRI morphometry in Parkinsonian syndromes. <i>Movement Disorders</i> , 2017, 32, 778-782. | 3.9 | 67 |
| 137 | PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i> . <i>EMBO Molecular Medicine</i> , 2017, 9, 371-384. | 6.9 | 93 |
| 138 | Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. <i>Acta Neuropathologica</i> , 2017, 133, 825-837. | 7.7 | 90 |
| 139 | Differentiation of atypical Parkinson syndromes. <i>Journal of Neural Transmission</i> , 2017, 124, 997-1004. | 2.8 | 30 |
| 140 | Multiple System Atrophy. , 2017, , 183-192. | | 2 |
| 141 | Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017, 32, 995-1005. | 3.9 | 121 |
| 142 | Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. <i>Movement Disorders</i> , 2017, 32, 955-971. | 3.9 | 179 |
| 143 | Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017, 32, 853-864. | 3.9 | 1,402 |
| 144 | Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials. <i>Movement Disorders</i> , 2017, 32, 842-852. | 3.9 | 52 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 145 | Reply to: MRI measures of brainstem in parkinsonian syndromes: Where we stand and where we need to go. <i>Movement Disorders</i> , 2017, 32, 1261-1262. | 3.9 | 1 |
| 146 | Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. <i>Lancet Neurology</i> , The, 2017, 16, 552-563. | 10.2 | 303 |
| 147 | Tau Diagnostics and Clinical Studies. <i>Journal of Molecular Neuroscience</i> , 2017, 63, 123-130. | 2.3 | 11 |
| 148 | Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells. <i>Scientific Reports</i> , 2017, 7, 11469. | 3.3 | 52 |
| 149 | c.207C>G mutation in sepiapterin reductase causes autosomal dominant dopa-responsive dystonia. <i>Neurology: Genetics</i> , 2017, 3, e197. | 1.9 | 10 |
| 150 | Drug Safety Analysis in a Real-Life Cohort of Parkinsonâ€™s Disease Patients with Polypharmacy. <i>CNS Drugs</i> , 2017, 31, 1093-1102. | 5.9 | 15 |
| 151 | Preclinical Analysis of Fetal Human Mesencephalic Neural Progenitor Cell Lines: Characterization and Safety In Vitro and In Vivo. <i>Stem Cells Translational Medicine</i> , 2017, 6, 576-588. | 3.3 | 11 |
| 152 | [18F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 440. | 3.4 | 58 |
| 153 | The Differential Diagnosis and Treatment of Atypical Parkinsonism. <i>Deutsches A&#x0308;rztblatt International</i> , 2016, 113, 61-9. | 0.9 | 135 |
| 154 | Differential effects of social and physical environmental enrichment on brain plasticity, cognition, and ultrasonic communication in rats. <i>Journal of Comparative Neurology</i> , 2016, 524, 1586-1607. | 1.6 | 122 |
| 155 | L-DOPA-induced dyskinesia is associated with a deficient numerical downregulation of striatal tyrosine hydroxylase mRNA-expressing neurons. <i>Neuroscience</i> , 2016, 331, 120-133. | 2.3 | 7 |
| 156 | A Review of Treatment Options for Progressive Supranuclear Palsy. <i>CNS Drugs</i> , 2016, 30, 629-636. | 5.9 | 36 |
| 157 | Parkinson's disease: SNCA-, PARK2-, and LRRK2- targeting microRNAs elevated in cingulate gyrus. <i>Parkinsonism and Related Disorders</i> , 2016, 33, 115-121. | 2.2 | 72 |
| 158 | Chronic consumption of <i>Annona muricata</i> juice triggers and aggravates cerebral tau phosphorylation in wild-type and <i>MAPT</i> transgenic mice. <i>Journal of Neurochemistry</i> , 2016, 139, 624-639. | 3.9 | 26 |
| 159 | Differentiation of neurodegenerative parkinsonian syndromes by volumetric magnetic resonance imaging analysis and support vector machine classification. <i>Movement Disorders</i> , 2016, 31, 1506-1517. | 3.9 | 120 |
| 160 | A genome-wide association study in multiple system atrophy. <i>Neurology</i> , 2016, 87, 1591-1598. | 1.1 | 139 |
| 161 | Current Treatment of Multiple System Atrophy. <i>Current Treatment Options in Neurology</i> , 2016, 18, 51. | 1.8 | 9 |
| 162 | microRNA profiling: increased expression of miR-147a and miR-518e in progressive supranuclear palsy (PSP). <i>Neurogenetics</i> , 2016, 17, 165-171. | 1.4 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 163 | The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. <i>Journal of Neural Transmission</i> , 2016, 123, 439-445. | 2.8 | 32 |
| 164 | Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy. <i>Movement Disorders</i> , 2016, 31, 742-747. | 3.9 | 29 |
| 165 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222. | 9.1 | 4,701 |
| 166 | Progressive supranuclear palsy: progression and survival. <i>Journal of Neurology</i> , 2016, 263, 380-389. | 3.6 | 55 |
| 167 | The phenotypic spectrum of progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2016, 22, S34-S36. | 2.2 | 65 |
| 168 | Psychosis in Parkinson's disease: identification, prevention and treatment. <i>Journal of Neural Transmission</i> , 2016, 123, 45-50. | 2.8 | 39 |
| 169 | Early Neurodegeneration in the Brain of a Child Without Functional PKR-like Endoplasmic Reticulum Kinase. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 850-857. | 1.7 | 27 |
| 170 | From a single nucleotide polymorphism to tau pathology: Apoptosin is the missing link. <i>Movement Disorders</i> , 2015, 30, 1871-1872. | 3.9 | 2 |
| 171 | Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. <i>Nature Communications</i> , 2015, 6, 7247. | 12.8 | 170 |
| 172 | A new dopaminergic nigro-olfactory projection. <i>Acta Neuropathologica</i> , 2015, 130, 333-348. | 7.7 | 89 |
| 173 | Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease. <i>Journal of the Neurological Sciences</i> , 2015, 356, 129-136. | 0.6 | 23 |
| 174 | Improved preparation of nasal lavage fluid (NLF) as a noninvasive sample for proteomic biomarker discovery. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2015, 1854, 741-745. | 2.3 | 6 |
| 175 | Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease. <i>Neuropharmacology</i> , 2015, 95, 367-376. | 4.1 | 51 |
| 176 | Systemically administered neuregulin-1 β rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease. <i>Journal of Neurochemistry</i> , 2015, 133, 590-597. | 3.9 | 22 |
| 177 | Neurotoxicity of Dietary Supplements from Annonaceae Species. <i>International Journal of Toxicology</i> , 2015, 34, 543-550. | 1.2 | 29 |
| 178 | Diesterified Derivatives of 5-Iodo-2-Deoxyuridine as Cerebral Tumor Tracers. <i>PLoS ONE</i> , 2014, 9, e102397. | 2.5 | 2 |
| 179 | Mitochondrial Complex 1 Inhibition Increases 4-Repeat Isoform Tau by SRSF2 Upregulation. <i>PLoS ONE</i> , 2014, 9, e113070. | 2.5 | 21 |
| 180 | Piericidin A Aggravates Tau Pathology in P301S Transgenic Mice. <i>PLoS ONE</i> , 2014, 9, e113557. | 2.5 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 181 | Extracellular Vesicle-Mediated Transfer of Genetic Information between the Hematopoietic System and the Brain in Response to Inflammation. <i>PLoS Biology</i> , 2014, 12, e1001874. | 5.6 | 312 |
| 182 | The phenotypic spectrum of progressive supranuclear palsy: A retrospective multicenter study of 100 definite cases. <i>Movement Disorders</i> , 2014, 29, 1758-1766. | 3.9 | 286 |
| 183 | Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. <i>Movement Disorders</i> , 2014, 29, 479-487. | 3.9 | 130 |
| 184 | Memory deficits correlate with tau and spine pathology in <i>P301S</i> <i>MAPT</i> transgenic mice. <i>Neuropathology and Applied Neurobiology</i> , 2014, 40, 833-843. | 3.2 | 35 |
| 185 | A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. <i>Movement Disorders</i> , 2014, 29, 470-478. | 3.9 | 251 |
| 186 | Origin of the dopaminergic innervation of adult neurogenic areas. <i>Journal of Comparative Neurology</i> , 2014, 522, 2336-2348. | 1.6 | 36 |
| 187 | Selegiline normalizes, while L-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease. <i>Neuropharmacology</i> , 2014, 79, 212-221. | 4.1 | 21 |
| 188 | Transcriptional and structural plasticity of tyrosine hydroxylase expressing neurons in both striatum and nucleus accumbens following dopaminergic denervation. <i>Journal of Chemical Neuroanatomy</i> , 2014, 61-62, 169-175. | 2.1 | 7 |
| 189 | Extracellular vesicle-mediated transfer of genetic information between the hematopoietic system and the brain in response to inflammation. <i>Journal of Neuroimmunology</i> , 2014, 275, 165. | 2.3 | 2 |
| 190 | Subcellular expression and neuroprotective effects of SK channels in human dopaminergic neurons. <i>Cell Death and Disease</i> , 2014, 5, e999-e999. | 6.3 | 56 |
| 191 | Annonacin, a natural lipophilic mitochondrial complex I inhibitor, increases phosphorylation of tau in the brain of FTDP-17 transgenic mice. <i>Experimental Neurology</i> , 2014, 253, 113-125. | 4.1 | 39 |
| 192 | Trifluoperazine rescues human dopaminergic cells from wild-type α -synuclein-induced toxicity. <i>Neurobiology of Aging</i> , 2014, 35, 1700-1711. | 3.1 | 48 |
| 193 | Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. <i>Lancet Neurology</i> , The, 2014, 13, 676-685. | 10.2 | 245 |
| 194 | High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 822-832. | 3.7 | 114 |
| 195 | Tau Silencing by siRNA in the P301S Mouse Model of Tauopathy. <i>Current Gene Therapy</i> , 2014, 14, 343-351. | 2.0 | 44 |
| 196 | Levetiracetam but not valproate inhibits function of CD8+ T lymphocytes. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2013, 22, 462-466. | 2.0 | 36 |
| 197 | Effect of long-term treatment with pramipexole or levodopa on presynaptic markers assessed by longitudinal [¹²³ I]FP-CIT SPECT and histochemistry. <i>NeuroImage</i> , 2013, 79, 191-200. | 4.2 | 12 |
| 198 | Atypical parkinsonism. <i>Current Opinion in Neurology</i> , 2013, 26, 401-405. | 3.6 | 49 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 199 | Accuracy of the national institute for neurological disorders and stroke/society for progressive supranuclear palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2013, 28, 504-509. | 3.9 | 132 |
| 200 | Quantitative evaluation of the human subventricular zone. <i>Brain</i> , 2012, 135, e221-e221. | 7.6 | 9 |
| 201 | Brain-resident microglia predominate over infiltrating myeloid cells in activation, phagocytosis and interaction with T-lymphocytes in the MPTP mouse model of Parkinson disease. <i>Experimental Neurology</i> , 2012, 238, 183-191. | 4.1 | 92 |
| 202 | Neuregulin-1 receptor tyrosine kinase ErbB4 is upregulated in midbrain dopaminergic neurons in Parkinson disease. <i>Neuroscience Letters</i> , 2012, 531, 209-214. | 2.1 | 22 |
| 203 | Clinical pain and experimental pain sensitivity in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 606-608. | 2.2 | 19 |
| 204 | Validation of mobile eye-tracking as novel and efficient means for differentiating progressive supranuclear palsy from Parkinson's disease. <i>Frontiers in Behavioral Neuroscience</i> , 2012, 6, 88. | 2.0 | 44 |
| 205 | Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. <i>Nature Genetics</i> , 2011, 43, 699-705. | 21.4 | 502 |
| 206 | Biodistribution and brain permeability of the extracellular domain of neuregulin-1 ^{Δ21} . <i>Neuropharmacology</i> , 2011, 61, 1413-1418. | 4.1 | 28 |
| 207 | Possible Involvement of Complement Factor C1q in the Clearance of Extracellular Neuromelanin From the Substantia Nigra in Parkinson Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 125-132. | 1.7 | 74 |
| 208 | Systemic administration of neuregulin ^{Δ1Δ2} protects dopaminergic neurons in a mouse model of Parkinson's disease. <i>Journal of Neurochemistry</i> , 2011, 117, 1066-1074. | 3.9 | 68 |
| 209 | Upregulation of microglial C1q expression has no effects on nigrostriatal dopaminergic injury in the MPTP mouse model of Parkinson disease. <i>Journal of Neuroimmunology</i> , 2011, 236, 39-46. | 2.3 | 34 |
| 210 | Magnetic resonance imaging in progressive supranuclear palsy. <i>Journal of Neurology</i> , 2011, 258, 549-558. | 3.6 | 44 |
| 211 | Cost-of-illness in multiple system atrophy and progressive supranuclear palsy. <i>Journal of Neurology</i> , 2011, 258, 1827-1834. | 3.6 | 11 |
| 212 | Mitochondrial Dysfunction as a Therapeutic Target in Progressive Supranuclear Palsy. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 684-689. | 2.3 | 19 |
| 213 | Hypodipsia discriminates progressive supranuclear palsy from other parkinsonian syndromes. <i>Movement Disorders</i> , 2011, 26, 901-905. | 3.9 | 3 |
| 214 | Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 6632-6637. | 7.1 | 184 |
| 215 | Health-Related Quality of Life in Multiple System Atrophy and Progressive Supranuclear Palsy. <i>Neurodegenerative Diseases</i> , 2011, 8, 438-446. | 1.4 | 53 |
| 216 | Cerebral bioimaging of Cu, Fe, Zn, and Mn in the MPTP mouse model of Parkinson's disease using laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS). <i>Journal of the American Society for Mass Spectrometry</i> , 2010, 21, 161-171. | 2.8 | 181 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 217 | In vivo demonstration of microstructural brain pathology in progressive supranuclear palsy: A DTI study using TBSS. <i>Movement Disorders</i> , 2010, 25, 1232-1238. | 3.9 | 70 |
| 218 | A brain-specific isoform of mitochondrial apoptosis-inducing factor: AIF2. <i>Cell Death and Differentiation</i> , 2010, 17, 1155-1166. | 11.2 | 37 |
| 219 | Rational therapeutic approaches to progressive supranuclear palsy. <i>Brain</i> , 2010, 133, 1578-1590. | 7.6 | 83 |
| 220 | Zonisamide: Aspects in neuroprotection. <i>Experimental Neurology</i> , 2010, 224, 336-339. | 4.1 | 19 |
| 221 | Nigrostriatal upregulation of 5-HT _{2A} receptors correlates with motor dysfunction in progressive supranuclear palsy. <i>Movement Disorders</i> , 2009, 24, 1170-1175. | 3.9 | 13 |
| 222 | Rostro-Caudal Gradual Loss of Cellular Diversity Within the Periventricular Regions of the Ventricular System. <i>Stem Cells</i> , 2009, 27, 928-941. | 3.2 | 39 |
| 223 | <i>In vivo</i> Evidence for Cerebral Depletion in High-Energy Phosphates in Progressive Supranuclear Palsy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009, 29, 861-870. | 4.3 | 43 |
| 224 | Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. <i>European Journal of Neurology</i> , 2009, 16, 297-309. | 3.3 | 170 |
| 225 | New insights into the relationship of neurogenesis and affect: tickling induces hippocampal cell proliferation in rats emitting appetitive 50-kHz ultrasonic vocalizations. <i>Neuroscience</i> , 2009, 163, 1024-1030. | 2.3 | 53 |
| 226 | Neurogenesis in Substantia Nigra of Parkinsonian Brains?. , 2009, , 279-285. | | 23 |
| 227 | Natural lipophilic inhibitors of mitochondrial complex I are candidate toxins for sporadic neurodegenerative tau pathologies. <i>Experimental Neurology</i> , 2009, 220, 133-142. | 4.1 | 76 |
| 228 | Neurodegenerative Diseases: Neurotoxins as Sufficient Etiologic Agents?. <i>NeuroMolecular Medicine</i> , 2008, 10, 1-9. | 3.4 | 54 |
| 229 | Short-term effects of coenzyme Q ₁₀ in progressive supranuclear palsy: A randomized, placebo-controlled trial. <i>Movement Disorders</i> , 2008, 23, 942-949. | 3.9 | 135 |
| 230 | Deficiency of Aph1B/C-Î³-secretase disturbs Nrg1 cleavage and sensorimotor gating that can be reversed with antipsychotic treatment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 9775-9780. | 7.1 | 77 |
| 231 | Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and Î±-synuclein-deleted mice. <i>Experimental Neurology</i> , 2008, 210, 182-193. | 4.1 | 135 |
| 232 | M. Parkinson - Zukünftige Therapieoptionen aus der Grundlagenforschung. <i>E-Neuroforum</i> , 2008, 14, 234-241. | 0.1 | 0 |
| 233 | Activation of the subventricular zone in multiple sclerosis: Evidence for early glial progenitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 4694-4699. | 7.1 | 299 |
| 234 | The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 3585-3590. | 7.1 | 245 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 235 | Glia Protects Neurons against Extracellular Human Neuromelanin. <i>Neurodegenerative Diseases</i> , 2007, 4, 218-226. | 1.4 | 18 |
| 236 | Atypical parkinsonism in Guadeloupe: a common risk factor for two closely related phenotypes?. <i>Brain</i> , 2007, 130, 816-827. | 7.6 | 99 |
| 237 | Annonacin, a Natural Mitochondrial Complex I Inhibitor, Causes Tau Pathology in Cultured Neurons. <i>Journal of Neuroscience</i> , 2007, 27, 7827-7837. | 3.6 | 176 |
| 238 | Hyperkalaemia in a tetraplegic adolescent due to de novo sodium channel mutation. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 1449-1451. | 0.7 | 2 |
| 239 | Quantitative [123I]FP-CIT pinhole SPECT imaging predicts striatal dopamine levels, but not number of nigral neurons in different mouse models of Parkinson's disease. <i>NeuroImage</i> , 2007, 38, 5-12. | 4.2 | 39 |
| 240 | Dopamine and adult neurogenesis. <i>Journal of Neurochemistry</i> , 2007, 100, 587-595. | 3.9 | 173 |
| 241 | New striatal dopamine neurons in MPTP-treated macaques result from a phenotypic shift and not neurogenesis. <i>Brain</i> , 2006, 129, 1194-1200. | 7.6 | 124 |
| 242 | Dopaminergic Substantia Nigra Neurons Project Topographically Organized to the Subventricular Zone and Stimulate Precursor Cell Proliferation in Aged Primates. <i>Journal of Neuroscience</i> , 2006, 26, 2321-2325. | 3.6 | 138 |
| 243 | The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. <i>Journal of Neurochemistry</i> , 2005, 95, 930-939. | 3.9 | 183 |
| 244 | Experimental evidence for a toxic etiology of tropical parkinsonism. <i>Movement Disorders</i> , 2005, 20, 118-119. | 3.9 | 18 |
| 245 | Quantification of acetogenins in <i>Annona muricata</i> linked to atypical parkinsonism in guadeloupe. <i>Movement Disorders</i> , 2005, 20, 1629-1633. | 3.9 | 103 |
| 246 | Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe. <i>Journal of Neurochemistry</i> , 2004, 88, 63-69. | 3.9 | 187 |
| 247 | Dopamine depletion impairs precursor cell proliferation in Parkinson disease. <i>Nature Neuroscience</i> , 2004, 7, 726-735. | 14.8 | 842 |
| 248 | Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. <i>Journal of Neurochemistry</i> , 2003, 84, 491-502. | 3.9 | 284 |
| 249 | Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. <i>Journal of Neurochemistry</i> , 2003, 86, 1297-1307. | 3.9 | 239 |
| 250 | Rat fetal ventral mesencephalon grown as solid tissue cultures: influence of culture time and BDNF treatment on dopamine neuron survival and function. <i>Brain Research</i> , 1998, 813, 313-322. | 2.2 | 48 |
| 251 | Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , 0, , . | 0.8 | 2 |